in a halfdozen male
staff members who had been waiting outside in a secretary's office. After
introductions they all moved to a conference area of the office suite,
seating themselves around a table with Camperdown at the head.
The newcomers included the director of research, Dr. Vincent Lord, a
r~cently recruited, youngish scientist; an elderly vice president of sales
who was shortly to retire; and four others, including Sam Hawthorne. With
the exception of Sam-the only one Celia had met previously-the others
regarded her with frank curiosity.
The new drug under consideration, Camperdown explained for Celia's benefit,
was not a product developed by Felding-Roth, but had been obtained under
license from a West German company, Chemie-Griinenthal.
"It is a sedative, one of the safest ever discovered," the president
declared, "and it produces a normal, refreshing sleep without unpleasant
morning-after grogginess." The product had no significant side effects, he
continued, and was so safe it could be given to small children. The
sedative was already on sale, and popular, in almost every major country
except the United States. Now, Felding-Roth was fortunate in having the
American rights.
The name of the drug, Mr. Camperdown added, was Thalidomide.
Despite Thalidomide's proven safety record, trials of the drug on humans
were required in the United States before its sale would be approved by the
Food and Drug Administration. "In the circumstances, with all that
first-rate foreign data," Camperdown grumbled, "it's a silly, bureaucratic
requirement, but we have to live with it."
A discussion followed about where and how the U.S. trials of Thalidomide
would be carried out. The director of research, Dr.
47
Lord, favored recruitment of fifty or so physicians in private practice
who would g1ve the drug to patients, then report results which
Felding-Roth would submit to FDA. "There should be a mix of general
practitioners, internists, psychiatrists, and obstetricians," he declared.
The vice president of sales demanded, "How long will all that ngmarole
take?"
"Probably three months."
"Could you make it two? We need this product on the market."
"I think so."
Someone else, though, expressed concern about the trials being so
widespread. Wouldn't they be simpler and reporting be faster in a
concentrated environment such as a hospital?
After several minutes of discussion Camperdown interjected with a smile,
"Perhaps our young lady guest has some thoughts on the subject."
"Yes, I have," Celia said.
All heads turned toward her.
She spoke carefully, aware that her presence here was unusual, even
privileged; therefore it would be foolish to spoil the opportunity by
seeming too assured or brash.
"One thing that could be worrisome," Celia said, "is the suggestion that
obstetricians prescribe this drug. This means pregnant women would be
taking it, and it's usually advised that pregnancy is not a time for
experimenting in any way."
Dr. Lord interrupted testily. "In this case that doesn't apply.
Thalidomide has been widely used in Europe and elsewhere, and those
taking it have included pregnant women."
"Just the same," Sam Hawthorne put in quietly, "Mrs. Jordan has a point."
Celia continued, "A question which might be asked is this: Who are the
people who have the most trouble sleeping, and therefore need a sleeping
pill? Well, based on my experience in detailingvisiting hospitals and
institutions, as well as doctors-I'd say old people, especially geriatric
patients."
She had the group's attention. Several around the table nodded agreement
at the last remark. Dr. Lord, his face set stiffly, did not.
"So what I'd recommend," Celia said, "is that our testing of Thalidomide
be done in one or two old people's homes. If it's of any use, I know of
two of them--one in Lincoln, Nebraska, the other outside Plainfield in
this state. Both are well run and efficient, and
48
wouid keep good
Kristin Billerbeck
Joan Wolf
Leslie Ford
Kelly Lucille
Eleanor Coerr, Ronald Himler
Marjorie Moore
Sandy Appleyard
Kate Breslin
Linda Cassidy Lewis
Racquel Reck